Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform OXFORD, United Kingdom and SAN JOSE, Calif. and SHANGHAI, China, Jan. 19, 2021 (GLOBE NEWSWIRE) -- WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics...

Oxford BioTherapeutics (OBT) Announces Second Oncology Drug Candidate Selected to Advance into Formal IND Enabling Studies from Boehringer Ingelheim (BI) Collaboration The Boehringer Ingelheim drug candidates are two of several assets approaching or in clinical development whose discovery has been enabled by OBT’s proprietary OGAP® target discovery platform OBT...

Oxford BioTherapeutics Initiates Dose-Escalation Portion of U.S. Phase I Clinical Trial for OBT076 in Patients with Advanced Solid Tumors Dose-escalation starting at a dose based on results from a European study sponsored by partner, Menarini Ricerche. Phase I program includes two U.S. expansion cohorts: (1) High risk cohort of HER2...

Oxford BioTherapeutics Announces Receipt of a Milestone Payment as Boehringer Ingelheim Advances an Oncology Drug Candidate OXFORD, United Kingdom and SAN JOSE, Calif., June 25, 2019 (GLOBE NEWSWIRE) -- Oxford BioTherapeutics Ltd. (“OBT”), a clinical stage oncology company with a pipeline of immuno-oncology and antibody...